Trials / Unknown
UnknownNCT05872867
Study of WM-A1-3389 in Participants With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer (MK-3475-E90/KEYNOTE-E90)
An Open-label, Dose-escalation, Phase 1 Study to Investigate the Safety and Tolerability of WM-A1-3389, in Combination With Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 54 (estimated)
- Sponsor
- Wellmarker Bio · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the present study is to determine the safety, tolerability, and efficacy of WM-A1-3389 in combination with pembrolizumab in participants with advanced or metastatic solid tumors and non-small cell lung cancer (NSCLC).
Conditions
- Advanced Solid Tumor
- Metastatic Solid Tumor
- Lung Cancer
- Colorectal Cancer
- Pancreatic Cancer
- Cholangiocarcinoma
- Head and Neck Cancer
- Non Small Cell Lung Cancer
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | WM-A1-3389 | Anti-IGSF1 (Immunoglobulin superfamily member 1) |
| BIOLOGICAL | Pembrolizumab | Anti-PD-1(Programmed cell death protein 1) |
Timeline
- Start date
- 2024-03-14
- Primary completion
- 2026-02-22
- Completion
- 2026-02-22
- First posted
- 2023-05-24
- Last updated
- 2024-03-12
Locations
2 sites across 1 country: South Korea
Source: ClinicalTrials.gov record NCT05872867. Inclusion in this directory is not an endorsement.